CLINICAL TRIAL: FACTORS THAT ALTER SKELETAL RESPONSES TO PTH

临床试验：改变骨骼对 PTH 反应的因素

• 批准号: 7731244
• 负责人: Robert Marshall Neer
• 金额: $ 2.2万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731244
• 关键词: Animals; Architecture; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Fracture; Funding; Grant; Human; Incidence; Institution; Osteogenesis; Osteoporosis; Parathyroid Hormones; Participant; Patients; Research; Research Personnel; Resources; Skeletal system; Source; Testing; United States National Institutes of Health; Woman; bone; hormone therapy; human PTH protein; reconstitution; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Parathyroid hormone (PTH) stimulates bone formation and reconstitutes bone micro-architecture in women with osteoporosis and markedly reduces the incidence of new fractures. But PTH does not cure osteoporosis in many patients, even though it routinely cures osteoporosis in experimental animals. One reason PTH fails to cure all humans is that PTH-stimulated increases in bone formation dissipate as PTH therapy continues. This study tests whether slowly increasing the dose of PTH prolongs its effects on bone formation. In addition, studies among the participants investigate why PTH's effects on bone formation decline despite continued treatment.

这个子项目是众多研究子项目之一